AK177 is an allosteric activator of IRE1α ribonuclease, with values of 480 nM and 180 nM against non-phosphorylated and phosphorylated IRE1α, respectively.\n

AJ-3941 is an orally active cerebrovascular-selective Calcium Channel antagonist having anti-lipid peroxidative action. AJ-3941 can ameliorate the brain infarction and edema after permanent focal cerebral ischemia.

AI 3-25755 (OMS-403) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. AI 3-25755 can be used for research on opioid abuse and smoking cessation.

AgrC-IN-1 is an AgrC inhibitor with an IC50 of 3.5 μM against Staphylococcus aureus AgrC. AgrC-IN-1 competitively binds to AgrC, inhibiting its autophosphorylation activity in Staphylococcus aureus. AgrC-IN-1 inhibits quorum sensing in Staphylococcus aureus, blocking virulence factor production. AgrC-IN-1 can be used for the research of Staphylococcus aureus infections.

AGN-191659 is an orally active RAR/RXR agonist with EC50 values of 11 nM, 23 nM, and 37 nM for RXRα, RARβ, and RARγ, respectively. AGN-191659 activates RXRα, RARβ and RARγ to induce gene transcription. AGN-191659 induces tissue transglutaminase activity, inhibits ornithine decarboxylase activity induced by tumor promoters, and suppresses chondrogenesis. AGN-191659 reverses basic fibroblast growth factor-induced endothelial cell proliferation. AGN-191659 induces hypertriglyceridemia in rat models. AGN-191659 inhibits total heparin-releasable lipase activity. AGN-191659 can be used in research related to promyelocytic leukemia and hypertriglyceridemia.

AGN-190383 is a bee venom phospholipase A2 inhibitor. AGN 190383 inhibits both hormone-operated and depolarization-dependent calcium mobilization as well as fMLP stimulated increases in free cytosolic calcium. AGN-190383 has anti-inflammatory activity.

AGN 192403 (BRD4780) is a potent and selective imidazoline-1 receptor antagonist with a Ki value of 42 nM. AGN 192403 is also a TMED9 inhibitor. AGN 192403 shows protective effects on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. AGN 192403 mitigates the proliferation and migration of differentiated glioma tumor cells. AGN 192403 can be used for glioma tumor and neurological diseases research.

AG-024104 is a CDK inhibitor with Ki values of 2.3 nM (CDK1/cyclinB), 1.8 nM (CDK2/cyclinA), and 0.67 nM (CDK4/cyclinD). AG-024104 functionally inhibits kinase activity of CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD. AG-024104 serves as a negative control for peripheral leukocyte toxicity studies in preclinical development.

AFP464 (NSC710464) is a prodrug of Aminoflavone and an agonist of the aryl hydrocarbon receptor (AhR). AFP464 downregulates the expression of α6-integrin (α6-integrin), inhibits breast tumor growth, reduces the population of tumor-initiating cells, disrupts mammosphere structure, induces the formation of mucin lake clusters, triggers DNA damage, and exerts antiproliferative activity. AFP464 is rapidly converted to Aminoflavone by nonspecific esterases in plasma and cell culture media. AFP464 is applicable to research related to breast cancer.

Aescigenin is a triterpenoid saponin compound that can be found in Aesculus hippocastanum. Aescigenin is the main component of sodium β-aescin, a compound that has the functions of reducing tissue edema, improving microcirculation, and anti-inflammation. It can be used in research on Bell's palsy.

AEG40826 (HGS1029), a second mitochondria-derived activator of caspases (SMAC) mimetic, is an inhibitor of apoptosis (IAP) inhibitor. AEG40826 degrades cellular IAP1 (cIAP1) and blocks TNF-α pro-survival signaling. AEG40826 can be used for cancer research.

ADP receptor-IN-1 (compound 21) is a platelet ADP receptor inhibitor. ADP receptor-IN-1 shows both IC50 values <10 μM at a platelet ADP receptor binding assay and aggregation using a platelet-rich plasma assay.

Adipic acid monoethyl ester is a PROTAC linker that can be used in the synthesis of PROTACs.

Adenosine receptor antagonist 7 is an orally active triple A1/A2A/A2B adenosine receptor antagonist with Ki values of 1.5, 0.6 and 21 nM. Adenosine receptor antagonist 7 shows potent inhibitory activity (IC50 = 0.8 nM) of cAMP production in A2AR-HEK293 cells. Adenosine receptor antagonist 7 can enhance infiltration of effector T cells and increase the CD8+/Treg ratio companied with Avelumab. Adenosine receptor antagonist 7can be used for the research of cancer, such as colon cancer.

ADD-196022 is an orally active antiepileptic and anticonvulsant agent. ADD-196022 shows ED50 values of 26.2 mg/kg and 5.79 mg/kg for intraperitoneal injection in mice and orally administration in rats. ADD-196022 can be used for the research of neurological disease.

ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan. Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody.

Adavosertib (AZD1775; MK-1775) acid (Compound 9) is a derivative of AZD1775 and can be used for the synthesis of PROTAC.

Ac-N-m-(CF3)2-Ph-C-Py (Compound F31) is an electrophilic fragment. Ac-N-m-(CF₃)₂-(phenyl)-C-(pyridyl) can be used in proteomics research.

Aclatonium napadisylate is a cholinergic agonist. Aclatonium napadisylate can increase amylase release and Ca2+ efflux. Aclatonium napadisylate can stimulate pancreatic exocrine secretion and increase motility and peristalsis of the gastrointestinal tract. Aclatonium napadisylate can be used for the research of gastrointestinal disorders.

ACI-19278 is a TDP-43 PET tracer with an average Kd of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [18F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions.

ACHM-025 is a prodrug, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent. ACHM-025 can be used for the research of cancer, such as leukemia.

AChE-IN-98 (Compound 26) is an AChE inhitibor, with an IC50 value of 7.3 μM for ee AChE. AChE-IN-98 is also a Coumarin derivative. AChE-IN-98 can be used in the research of Alzheimer's disease.

AChE-IN-105 (Compound C5) is a potent, mixed AChE inhibitor with an IC50 of 5.02 μM. AChE-IN-105 scavenges ROS, decreases Hydrogen peroxide-induced Caspase-3 activation, reduces activity of the Nrf2-ARE pathway. AChE-IN-105 prevents memory impairments in the Scopolamine-induced cognitive dysfunction zebrafish model. AChE-IN-105 has potent antioxidant activity. AChE-IN-105 can be used in the research of Alzheimer's disease.

AChE-IN-103 (Compound 10) is an inhibitor of ACh. AChE-IN-103 exhibits log IC50 values of 1.477 and 2.2 for models based on alignments I and II. AChE-IN-103 can be studied in research on Alzheimer’s disease.

AChE/MAO-B-IN-9 (Compound E12) is an orally active, selective, reversible, non-competitive AChE and MAO-B inhibitor, with an IC50 of 0.156 μM against electric eel AChE. AChE/MAO-B-IN-9 inhibits Aβ40/42 fibril formation, promotes Aβ fibril depolymerization, and inhibits Tau protein fibril formation. AChE/MAO-B-IN-9 exerts antioxidant and neuroprotective effects, and improves scopolamine-induced memory impairment in mice. AChE/MAO-B-IN-9 can be used for the research of Alzheimer's disease.

Acalabrutinib (Calquence) maleate is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib maleate demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib maleate can be used for CLL research. Acalabrutinib maleate is a click chemistry reagent, which contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

ABH is an arginase 1 (ARG1) inhibitor, with an IC50 of 311 nM against hARG1.

ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid-modulating agent. ABCA1 inducer 3 increases ABCA1 expression. ABCA1 inducer 3 upregulates hepatic Abcg5 and Abcg8 mRNA expression. ABCA1 inducer 3 promotes cholesterol efflux. ABCA1 inducer 3 improves hyperlipidemia.

ABC transporter modulator-5 (I-677-Isomer 2 (R configuration)) is a ABC modulator. ABC transporter modulator-5 is used in studies of ABC dysfunction.

ABCC6 modulator-3 (Compound I-71) is a ABCC6 activator with an EC50 < 1 μM. ABCC6 modulator-3 upregulates the expression of wild-type ABCC6. ABCC6 modulator-3 is used in research on diseases associated with ABC transporter dysfunction.